AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06498726 — intervention group
Intervention type: DEVICE
Intervention: transcranial doppler
Description: Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
Study NCT04093557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orton Score
Description: Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
Study NCT04093557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orton Score
Description: Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
Study NCT04093557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Typical Standard of Care
Description: Clinician usual practice of prescribing bowel preps to patient
Study NCT05162755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029
Description: S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
Study NCT05162755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S95029 and Sym021
Description: Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
Study NCT05162755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029 and Sym021 and anti-HER2 therapy
Description: Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
Study NCT05162755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab
Description: Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
Study NCT05765825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
Study NCT05765825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT05765825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT05765825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT05765825 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy (TRT)
Description: Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
Study NCT04910243 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Survey
Description: Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
Study NCT06255600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Definition-transcranial Direct Current Stimulation
Description: High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
Study NCT06255600 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High Definition-transcranial Direct Current Stimulation
Description: High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
Study NCT06255600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella Pyrenoidosa
Description: functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
Study NCT06255600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Chlorella Pyrenoidosa
Description: functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
Study NCT06721637 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.
Description: Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds
Study NCT06721637 — intervention group
Intervention type: DEVICE
Intervention: Group B (n = 20): received whole body vibration trained three times a week for 8 weeks
Description: The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
Study NCT06730724 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06730659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHT101
Description: CHT101: CD 70 UCAR T
Study NCT05964127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air flow device
Description: An air/powder device for surface decontamination
Study NCT05964127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand instruments
Description: Periodontal hand instruments
Study NCT05964127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access flap surgery
Description: To improve the surgical access for implant decontamination
Study NCT04909372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labelling
Description: Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact.
Study NCT06500650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred Occupational Therapy Intervention
Description: Person-centred Occupational Therapy Intervention
Study NCT04930705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with TempSure Applicator
Description: Subjects will receive up to 5 treatments on the abdomen.
Study NCT06062199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training in the A-DIVA scale and its failure prediction score
Description: Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
Study NCT06258954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D reconstruction
Description: 3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
Study NCT06258954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional method for selecting double lumen tube
Description: In control group, the size of DLT is based on patient's sex and height.
Study NCT05239117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plenhyage
Description: Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter.
Study NCT04565483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Prefilled Syringe
Description: Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Study NCT05777564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High intensity exercise
Description: High intensity exercise on a indoor aerobic exercise device.
Study NCT06345014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-89 [Uro-Vaxom® Capsule]
Description: Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
Study NCT06345014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-89 Placebo [Uro-Vaxom® Capsule Placebo]
Description: Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
Study NCT05635422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: isokinetism test
Description: measure of muscular fatigability by isokinetism
Study NCT05328024 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: anti-PD1
Study NCT06296004 — intervention group
Intervention type: DEVICE
Intervention: Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S
Description: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US
Study NCT05559671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Subunit (HZ/su) Vaccine
Description: Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
Study NCT05559671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
Study NCT04991636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioscan
Description: La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen.
Study NCT04651166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1g tranexamic acid mixed in 100mL saline or lactated ringer
Study NCT04651166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL saline or lactated ringers
Study NCT04747665 — intervention group
Intervention type: OTHER
Intervention: Patient and endoscopist reported experience
Description: Exploration of patient and endoscopists experiences of colonoscopy.
Study NCT05574829 — intervention group
Intervention type: DEVICE
Intervention: Esophageal manometry and monitoring of electrical activity of the diaphragm
Description: Esophageal manometry and monitoring of electrical activity of the diaphragm
Study NCT05337917 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical of the digital nerve
Description: All patients (cases and controls) were subject to surgical repair of digital nerve injury.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual motor imagery (MI)
Description: Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesthetic MI
Description: The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic-Hand Interaction with MI
Description: Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic-Hand Interaction without MI
Description: Subjects will perform the Robot-Hand Interaction without MI.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-Hand Interaction
Description: Subjects will interact with visual feedback of virtual robot actions on a monitor.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Action Observation
Description: Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
Study NCT04962698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: Subjects will rest without a task.
Study NCT05840562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Application of capsaicin patches 179 mg
Study NCT05840562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Administration of duloxetine
Study NCT06001541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-SUCCEED
Description: web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
Study NCT06001541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-SUCCEED
Description: web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
Study NCT05833659 — intervention group
Intervention type: PROCEDURE
Intervention: The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy
Description: Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
Study NCT05947435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid was administered in intravenous or locally within irrigation fluid
Study NCT05143112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19 CR-T cell
Description: Allogeneic CD19 CR-T cell infusion
Study NCT06052644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Dose-Response
Description: The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise.
Study NCT05293197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoCloud® (9 transducers)
Description: SonoCloud®, sonication: dose escalation 6 cycles of sonication
Study NCT04793373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syringe
Description: A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
Study NCT04793373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
Study NCT05313906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48+AK105+cisplatin
Description: RC48 plus AK105 and cisplatin
Study NCT05609799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
Study NCT05052710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will receive oral doses once daily from Days 2-11.
Study NCT05052710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive oral single doses on Day 1 and Day 11.
Study NCT06168253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Fading for Social Anxiety
Description: Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
Study NCT06168253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unhealthy Behavior Fading
Description: Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
Study NCT05005325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental group(Male)
Description: Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam